A retrospective study of the relationship between serum urate level and recurrent attacks of gouty arthritis: Evidence for reduction of recurrent gouty arthritis with antihyperuricemic therapy

Arthritis Care and Research

Volumn 51, Issue 3, 2004, Pages 321-325

  Shoji, Akira ^a   Yamanaka, Hisashi ^a   Kamatani, Naoyuki ^a  

^a TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

Author keywords

Antihyperuricemic drug; Gout; Serum urate

Indexed keywords

ALLOPURINOL; BENZBROMARONE; COLCHICINE; NONSTEROID ANTIINFLAMMATORY AGENT; URATE;

ADULT; AGED; ARTHRITIS; ARTICLE; FEMALE; GOUT; HUMAN; MAJOR CLINICAL STUDY; MALE; RECURRENT DISEASE; REGRESSION ANALYSIS; RETROSPECTIVE STUDY; TREATMENT OUTCOME; URIC ACID BLOOD LEVEL;

EID: 2642527090     PISSN: 21514658     EISSN: None     Source Type: Journal    
DOI: 10.1002/art.20405     Document Type: Article

References (15)

1. Becker MA. Clinical gout and the pathogenesis of hyperuricemia. In: Koopman WJ, editor. Arthritis and allied conditions, 14th edition. Philadelphia: Lippincott Williams & Wilkins; 2001. p. 2281-313.
2. Tarng DC, Lin HY, Shyong ML, Wang JS, Yang WC, Huang TP. Renal function in gout patients. Am J Nephrol 1995;15:31-7.
3. Perez-Ruiz F, Alonso-Ruiz A, Calabozo M, Herrero-Beites A, Garcia-Erauskin G, Ruiz-Lucea E. Efficacy of allopurinol and benzbromarone for the control of hyperuricaemia: a pathogenic approach to the treatment of primary chronic gout. Ann Rheum Dis 1998;57:545-9.
4. Schlesinger N, Baker DG, Schumacher HR Jr. How well have diagnostic tests and therapies for gout been evaluated? Curr Opin Rheumatol 1999;11:1-5.
5. Schlesinger N, Schumacher HR Jr. Gout: can management be improved? Curr Opin Rheumatol 2001;13:240-4.
6. Wallace SL, Robinson H, Masi AT, Decker JL, McCarty DJ, Yu TF. Preliminary criteria for the classification of the acute arthritis of primary gout. Arthritis Rheum 1977;20:895-900.
7. Yamanaka H, Togashi R, Hakoda M, Terai C, Kashiwazaki S, Dan T, Kamatani N. Optimal range of serum urate concentrations to minimize risk of gouty attacks during anti-hyperuricemic treatment. Adv Exp Med Biol 1998;431:13-8.
8. Yu TF. Pharmacokinetic and clinical studies of a new uricosuric agent: benzbromarone. J Rheumatol 1976;3:305-12.
9. Wortmann RL. Effective management of gout: an analogy. Am J Med 1998;105:513-4.
10. Beutler AM, Rull M, Schlesinger N, Baker DG, Hoffman BI, Schumacher HR Jr. Treatment with allopurinol decreases the number of acute gout attacks despite persistently elevated serum uric acid levels, Clin Exp Rheumatol 2001;19:595.
11. Emmerson BT. The management of gout. N Engl J Med 1996;334:445-51.
12. Edwards NL. Management of hyperuricemia. In: Koopman WJ, editor, Arthritis and allied conditions, 14th edition. Philadelphia: Lippincott Williams & Wilkins; 2001:2314-328.
13. Cameron JS, Simmonds HA, Use and abuse of allopurinol. BMJ 1987;294:1504-5.
14. Matzkies F. Effects and side effects of benzbromarone in the initial treatment of hyperuricemia and gout: results of a field study on 3899 patients. Fortschr Med 1978;96:1619-21.
15. Li-Yu J, Clayburne G, Sieck M, Beutler A, Rull M, Eisner E, et al. Treatment of chronic gout: can we determine when urate stores are depleted enough to prevent attacks of gout? J Rheumatol 2001;28:577-80.